NeuroMetrix, Inc. (NASDAQ:NURO) today announced the commercial availability of DPNCheck 2.0, the Company's latest point-of-care device that leverages gold-standard nerve conduction technology to detect peripheral
Gainers
NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The company's market cap stands at $2.8 million.